Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | PTGES | O14684 | 11/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9899775 | 1.00 | ALDH1A1 (0.40) | ALDH1A1PTGESPOLBSCN10A | |
| SCHEMBL14211217 | 0.89 | ALDH1A1 (0.41) | ALDH1A1POLB | |
| SCHEMBL14118420 | 0.87 | PTGES (0.40) | ALDH1A1PTGESPOLB | |
| SCHEMBL9942033 | 0.87 | PTGES (0.40) | ALDH1A1PTGESPOLB | |
| SCHEMBL9899704 | 0.86 | PTGES (0.41) | PTGESSCN10A | |
| SCHEMBL16882989 | 0.86 | PTGES (0.41) | PTGESSCN10A | |
| SCHEMBL9899702 | 0.86 | PTGES (0.41) | PTGESSCN10A | |
| SCHEMBL14211259 | 0.83 | ALDH1A1 (0.40) | ALDH1A1POLB | |
| SCHEMBL9899695 | 0.83 | ALDH1A1 (0.40) | ALDH1A1PTGESPOLB | |
| SCHEMBL9942031 | 0.83 | ALDH1A1 (0.40) | ALDH1A1PTGESPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2649071-B1 | Imidazo(4,5-b)pyridine-6-carboxamides as anti-inflammatory agents | OREXO AB (SE) | 2015-07-08 | — | — | EP | disclosed |
| EP-2649071-A1 | IMIDAZO(4,5-B)PYRIDINE-6-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS | Boehringer Ingelheim International GmbH (DE) | 2013-10-16 | — | — | EP | disclosed |
| US-8486968-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-16 | — | — | US | disclosed |
| US-20120309755-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-06 | — | — | US | disclosed |
| WO-2012076674-A1 | IMIDAZO(4,5-B)PYRIDINE-6-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309755-A1 | NOVEL COMPOUNDS | PTGER1, PTGS1, PTGES | ALDH1A1 112/4885PTGES 3/4885POLB 2270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.